文献速递类风湿关节炎

类风湿关节炎持续缓解患者将肿瘤坏死因子抑制剂逐渐减量至停药与维持稳定剂量的三年结果比较:一项多中心随机试验

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial.
PubMed 文献 · Arthritis Rheumatol · 2025-06-26

ARCTIC REWIND多中心开放标签非劣效性试验纳入持续缓解≥12个月的类风湿关节炎患者,随机分为TNFi逐渐减量至停药组或维持稳定剂量组,评估三年无复发生存与影像学进展。三年时减量组25%维持无复发,稳定组85%,复发风险比为9.4(95%CI 3.9-22.8,P<0.0001);影像学进展两组差异无统计学意义(风险差6.7%,95%CI -7.1%至20.5%,P=0.3)。

要点

  • 持续缓解的RA患者TNFi减量至停药后三年仅25%维持无复发,而稳定剂量组为85%。
  • 减量组复发风险显著升高,风险比为9.4(95%CI 3.9-22.8,P<0.0001)。
  • 影像学进展两组差异无统计学意义(风险差6.7%,95%CI -7.1%至20.5%,P=0.3)。

核心结论

  • 与维持稳定TNFi治疗相比,持续缓解的RA患者将TNFi逐渐减量至停药后三年仅少数维持无复发。
  • 两组影像学进展差异无统计学意义。

研究设计与样本

  • ARCTIC REWIND为多中心开放标签非劣效性试验,纳入持续缓解≥12个月且正在接受稳定TNFi治疗的RA患者,按1:1随机分为TNFi逐渐减量至停药组或继续稳定治疗组。
  • 共99例随机,92例接受分配治疗,80例完成三年随访。

主要发现

  • 基线基于44关节的疾病活动度评分平均为0.8,90%的患者联用传统合成改善病情抗风湿药。
  • 三年时减量组25%(95%CI 13%-38%)维持无复发,稳定组85%(95%CI 70%-93%),复发风险比为9.4(95%CI 3.9-22.8,P<0.0001)。
  • 减量组41例中6例(15%)出现影像学进展,稳定组38例中3例(8%)出现影像学进展(风险差6.7%,95%CI -7.1%至20.5%,P=0.3)。
  • 不良事件发生率减量组为81%,稳定组为89%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tapering of tumor necrosis factor inhibitor (TNFi) treatment in rheumatoid arthritis (RA) remission is debated. We assessed the effect of tapering TNFi to withdrawal versus continued stable TNFi on flare-free survival and joint damage progression over three years. METHODS: ARCTIC REWIND was a multicenter open-label, noninferiority trial that included patients with RA in remission for ≥12 months taking stable TNFi therapy. Patients were randomized 1:1 to taper TNFi to withdrawal or continue stable treatment. The primary end points of the current study were flare-free survival and radiographic progression over three years. Flare-free survival was analyzed by Kaplan-Meier methods, flare rates were analyzed by Cox regression, and radiographic progression was analyzed by logistic mixed-effects models. RESULTS: Of 99 randomized patients, 92 received the allocated therapy, and 80 completed the three-year follow-up. The mean baseline Disease Activity Score based on the 44 joint count was 0.8, and conventional synthetic disease-modifying antirheumatic drug comedication was used by 90% of patients. After three years, 25% (95% confidence interval [CI] 13%-38%) remained flare free in the tapering TNFi group, compared to 85% (95% CI 70%-93%) in the stable group, and the corresponding hazard ratio for flare was 9.4 (95% CI 3.9-22.8, P < 0.0001). In the tapering group, 6 of 41 (15%) experienced radiographic progression, compared with 3 of 38 (8%) in the stable group (risk difference 6.7%, 95% CI -7.1% to 20.5%, P = 0.3). Adverse events occurred in 81% of the patients in the tapering group and 89% of the patients in the stable group. CONCLUSION: In contrast to those receiving stable TNFi treatment, a minority of patients with RA in remission tapering TNFi to withdrawal remained flare free over three years. There was no statistically significant difference in radiographic progression between the groups.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kjørholt KE, Sundlisæter NP, Aga AB, et al. Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial. Arthritis Rheumatol. 2025. PMID: 40289847. doi:10.1002/art.43199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。